Mutation-resistant nano therapeutics inhibiting infection progress of RNA-virus, SARS-CoV-2

ACELLMED Sp. z o.o., the Silesian Medical Technology Park Kardio-Med Silesia and the University of Wrocław – Faculty of Biotechnology, have established cooperation for the implementation of a project co-financed by the Medical Research Agency under the “Call for proposals for the development of innovative therapeutic solutions using RNA technology.”  under the call ABM/2021/5.

The project is named: “Mutation-resistant nano therapeutics inhibiting infection progress of RNA-virus, SARS-CoV-2.”

PROJECT OBJECTIVE – development of R&D activity and competitiveness through implementation of R&D works, which will result in a drug inhibiting leukemia cell proliferation used during oncology therapy. The goal will be achieved by October 2025.

The main scientific objective is to develop an effective therapy for Sars-CoV-2 infection. Acellmed, the Silesian Medical Technology Park Kardio-Med Silesia and the University of Wroclaw aim to develop a drug that can be used to treat the progression of COVID-19 disease.

Project objectives:

Project implementation period: 01.09.2021-31.10.2025

Project value:

 



    [honeypot honeypot-315]